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Derivation of eggs or sperm from pluripotent stem cells or direct reprogramming from somatic cells would
have huge effects on assisted reproductive technology. Here we discuss important ethical, legal, and social
issues that would be raised by the development of such female or male gametes for clinical use.Recent advances in stemcell biology have
nowmade it conceivable that human eggs
or sperm could potentially be derived from
pluripotent stemcells or direct reprogram-
ming of somatic cells. Most notably, Sai-
tou andcolleagues recently demonstrated
the successful induction of sperm and oo-
cytes from mouse embryonic stem cells
(ESCs) and induced pluripotent stem cells
(iPSCs) (Hayashi et al., 2011, 2012).
Although there is room for improvement
in the protocols, the work abolished
several technical barriers in mouse cells
with the demonstration that viable prog-
eny could be derived from pluripotent
stem cells. Similarly, over the last decade,
much progress has been made in the dif-
ferentiation of human germ cells from
bothhumanembryonic stemcells (hESCs)
and human iPSCs (hiPSCs). A recent
report indicated that hiPSCs can be differ-
entiated into primordial germ cells (PGCs)
via use of bone morphogenetic proteins
(Panula et al., 2011). In addition, hESCs
and hiPSCs differentiated directly into
male germ cell lineages, including post-
meiotic, spermatid-like cells, without
receiving genetic manipulation (Easley
et al., 2012). Although production of hu-
man oocytes from female pluripotent
stem cells has not yet been described,
the data from the mouse experiments
may help overcome some of the critical
problems and lead to the rapid derivation
of human oocytes.
Five years have passed since an
international consortium published a
consensus paper on various issues con-
cerning stem-cell-derived gametes (The
Hinxton Group, 2008). The time is right toreconsider the research response to the
production of human germ cells in vitro
from PSCs or somatic cells, as well as
what steps might ensure the ability to
move research to clinical applications.
This research should improve our under-
standing of human developmental biology
andshouldcontribute toadvancingknowl-
edgeof thepathology,diagnosis, anduses
of assisted reproductive technology (ART).
As we move forward, however, many
ethical, legal, and social issues lie ahead.
One key issue is the need to assess the
function of induced germ cells; this im-
plies the need for research that tests
human induced sperm and eggs to deter-
mine if they can successfully participate in
fertilization and produce normal embryos.
For example, generation of sperm and
eggs positive for specific male and female
germ cell markers and negative for those
specific to pluripotent stem cells should
be ensured. Additionally, appropriate
epigenetic programming, properly im-
printed sperm and egg chromatin, and
appropriate organization of the sperm
and egg nucleus and mitochondrial struc-
ture should be evaluated. Thereafter, the
creation of human embryosmay, as a final
biological assay, be exceptionally neces-
sary in a preclinical stage to ensure safety
of the induced cells. Currently, many
countries allow derivation of hESCs from
surplus in vitro fertilization (IVF) embryos,
subject to some conditions, but many ju-
risdictions limit or ban production of
human embryos for research purposes.
This raises the question of where and un-
der what circumstances the research
necessary to explore the medical poten-Cell Stem Cell 1tial of human induced germ cells can be
legally and ethically performed. Should
such cells be brought to the clinic, a
different set of controversial issues will
appear. In this article, we scrutinize the
questions concerning embryo research
and point out some of the issues that
eventual clinical use will raise.
Creating Human Embryos
for Research
In fertility clinics, ART generally begins
with ovulation via hormonal stimulation
followed by oocyte retrieval for IVF. In
cases of male infertility, the use of intracy-
toplasmic sperm injection (ICSI) is often
required to produce viable embryos with
one or a few sperm. Following fertilization,
embryos are cultured, generally for
3–5 days, and one or more is selected
for transfer to the uterus (Niakan et al.,
2012). Remaining preimplantation em-
bryos are then either stored under cryo-
preservation for future embryo transfer
to a patient or discarded. Following suc-
cessful pregnancies, cryopreserved em-
bryos may subsequently be discarded,
given to other prospective parents, or
donated to research. Research that
makes use of surplus embryos must
meet guidelines of institutional review
boards (IRBs) or equivalent bodies, espe-
cially in terms of prior informed consent of
parental donors. Notably, the derivation of
hESC lines is generally conducted using
the existing and surplus embryos that
were originally created for ART and are
no longer required for reproductive pur-
poses. For many people, and govern-
ments, the fact that the embryos were3, August 1, 2013 ª2013 Elsevier Inc. 145
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is crucial to their ethical use for research
once intended reproductive uses are no
longer contemplated.
International Regulatory Landscape
Regarding national policy of human em-
bryo creation for research purposes, we
investigated 17 countries that permit
hESCderivation from the surplus embryos
(Table S1 available online). Fifteen of these
countries permit creation of embryos for
research purposes in at least some cir-
cumstances: Australia, Belgium, Canada,
China, Denmark, India, Israel, Japan,
Singapore, South Africa, South Korea,
Spain, Sweden, the UK, and the US (in
some but not all states). All of these coun-
tries, by statutes or by guidelines, limit the
culture period of the created embryo to
either the14thdayof embryodevelopment
or the formation of the primitive streak,
which begins roughly at that time. This re-
striction has been justified on the grounds
that the formation of the primitive streak
signifies the start of a unique, humanbeing
(The President’s Council on Bioethics,
2002). In someof thepermissive countries,
researchers are required to provide spe-
cific justification for why they need to
create embryos for research. In Australia,
Belgium, Canada, India, Israel, Japan,
Singapore, South Africa, South Korea,
Spain, and the UK, the laws or guidelines
require a public license or authorization
to create human embryos for research. In
addition to the need to account for the cre-
ation of embryos for research purposes,
some explanation for the decision not to
use surplus IVF embryos is also required
in the review process.
In countries that allow the creation of
embryos for research, therapeutic cloning
using somatic cell nuclear transfer is
frequently indicated as a permitted pur-
pose. Others include hESC derivation,
parthenogenesis, and special embryos
including ‘‘hybrid embryos’’ in Australia
and ‘‘cytoplasmic hybrids’’ in Singapore
and the UK. Belgium, Canada, Denmark,
Japan, and the UK permit research that
creates human embryos for improving or
providing instruction in ART. The Austra-
lian act indicated the possibility of creating
human embryos using ‘‘precursor cells’’
from human embryos. Notably, the ‘‘pre-
cursor cells’’ might be regarded as the
germ cells induced from hESCs, but not
from hiPSCs. Japan has guidelines for146 Cell Stem Cell 13, August 1, 2013 ª2013inducing germ cells from human iPSCs,
ESCs, and tissue-specific stem cells, but
those guidelines currently prohibit fertil-
ization using the induced germ cells.
Thus, it seems clear that researchers in
Australia, Belgium, Canada, Denmark,
and the UK, might, after prior consultation
or permission from a regulatory authority,
be allowed to create human embryos
and develop them in culture for about
14 days in order to investigate develop-
mental potential of the inducedgermcells.
In the US, current federal laws and NIH
guidelines only prohibit federal funding of
research that results in the destruction or
risk of damage to human embryos.
Research that does not receive federal
funding is not subject to that restriction.
In contrast, several states enacted stat-
utes that directly impact human embryo
research. These statutes vary widely (Na-
tional Conference of State Legislatures,
2008). The statutes in California, Connect-
icut, Illinois, Iowa, Maryland, Massachu-
setts, New Jersey, and New York
generally encourage embryonic stem cell
research, but with varying restrictions
(Table S1). On the other hand, some
states, such as Michigan and Louisiana,
discourage or ban human embryo
research including hESC research. Yet,
except in some states with restrictive pol-
icies, US researchers with nonfederal
funding may be allowed to create human
embryos using induced germ cells for
research, though perhaps after approval
by both a local stem cell research over-
sight committee as well as an IRB.
The Regulatory Process in Japan
To our knowledge, Japan is the only juris-
diction with a special guideline on human
germ cell induction from stem cells. In
Japan, hESC guidelines were established
by the Ministry of Education, Culture,
Sports, Science, and Technology (MEXT)
in 2001. The guidelines banned germ cell
induction research after considering po-
tential ethical issues raised by the crea-
tion of an individual with the induced
germ cells. In 2004, the Council for Sci-
ence and Technology Policy adopted a
basic policy, holding that in order to pre-
serve human dignity, human embryo cre-
ation for research purposes is in principle
not permitted. But, the policy contained
two exceptions: research for improving
or providing instruction in ART and hESC
derivation from surplus embryos. For theElsevier Inc.purpose of ART, only gametes donated
by infertility or gynecologic patients may
currently be used.
On November 30, 2007, Yamanaka and
colleagues reported the generation of
hiPSCs (Takahashi et al., 2007). One
week later, on December 7, 2007, Yama-
naka suggested that research on human
germ cell induction should be temporarily
restricted until MEXT established proper
guidelines. The Ministry issued a notifica-
tion informing research institutions of the
temporary prohibition on germ cell induc-
tion from hiPSCs on February 21, 2008,
just3monthsafter thederivationof hiPSCs
was reported. After this temporary prohibi-
tion, the MEXT Bioethics and Biosafety
Committee continued to investigate the
requirements that would permit the
research. Following 1 year of discussion,
the committee concluded that the ban on
germ cell induction could be conditionally
lifted considering major scientific and
medical benefits, such as elucidation of
gametogenesis, the pathologies of infer-
tility, and congenital diseases. However,
the ban on creating human embryos using
germ cells induced from iPSCs continued,
both because of the 2004 national basic
policy banning human embryo creation
for research purposes and because of
the perception of technical barriers for ob-
taining mature and fertile germ cells from
iPSCs or tissue stem cells at that time.
In 2010, the Ministry formulated
‘‘Guidelines on Research into Producing
Germ Cells from Human Induced Pluripo-
tent Stem Cells or Human Tissue Stem
Cells.’’ At about the same time, the Minis-
try revised the hESC utilization guidelines
to allow germ cell induction from hESCs.
The Japanese authorities thus acted
quickly to respond to ethical concerns
triggered by a scientific breakthrough,
imposing a temporary ban and then lifting
it, in part, within 2 years due to construc-
tive discussions by researchers, policy
makers, and the committee.
The Path Forward
The use of germ cells derived from plurip-
otent hESCs or iPSCs to create human
embryos for research purposes is legal
in some countries and not in others.
Except for Japan, no country seems to
have considered this issue directly. If hu-
man germ cells induced from pluripotent
stem cells are to have an opportunity to
be used in clinical applications, the
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tial as a final functional assay. However,
this functional assay should be limited in
use as an exceptional assay to evaluate
the developmental potential of induced
germ cells in a preclinical stage. Countries
will have to consider, or reconsider, their
positions on creation of human embryos
for research in light of this possible appli-
cation. In doing so, some countries may
want to consider whether, in terms of
moral status, embryos created for
research purposes from pluripotent
stem-cell-derived germ cells are similar
to or are different from other embryos.
The main difference that we see of
possible ethical significance is that em-
bryos created from induced germ cells
from hiPSCs would not require the pro-
cess of gamete donation, which, for
women, is unpleasant and risky. This dif-
ference, however, seems to be minor
compared to the overall similarities given
that all embryos have the potential to
become human life. As a result, all the em-
bryos created either for research or for
reproductive purposes deserve equiva-
lent moral respect.
The Social Effects of Successful
Research on Human Induced Germ
Cells
When we are able to generate germ cells
from human pluripotent stem cells or so-
matic cells, people may benefit, both
frommaking ART possible in cases where
few or no eggs or sperm are produced
and from improved understanding of and
treatment for reproductive failure. Autolo-
gous production of germ cells from plurip-
otent stem cells might provide hope for
patients who were never fertile or who
lost their fertility from chemotherapy, radi-
ation therapy, or other events but who
wish to have a child that carries half of
their genome. The creation of mature
metaphase II oocytes from the patient’s
own iPSCs might also provide a pool of
oocytes for use in age-related oocyte
senescence or to support a type of germ-
line gene therapy that replaces mitochon-
drial DNA in human oocytes by spindle
transfer for inherited mitochondrial dis-
eases (reviewed in Trounson and Dewitt,
2013). Induced germ cells could also be
useful in basic research and contribute
further to unveiling pathways of human
preimplantation development. This could
lead to findings that improve IVF successrates by providing new culture techniques
and improved cryopreservation methods.
Conversely, adoption of this kind of
technology without rigorous study could
have adverse consequences. The most
worrisome possibility is that children
conceived from germ cells differentiated
from pluripotent stem cells might suffer
serious health impairments, at birth, later
in childhood, or even in adulthood. Thalid-
omide and Diethylstilbestrol were power-
ful warnings about the possible dangers
of insufficiently tested interventions early
in embryonic development.
In addition to issues of physical safety,
the possible uses of human germ cells
differentiated from pluripotent stem cells
raise the possibility of perplexing new
ethical, legal, and social issues. For
example, posthumous conception using
germ cells that are infinitely generated
from iPSCsor somaticcellsmightproduce
unprecedentedsocial concerns, aswell as
novel pedigree diagrams. Or if germ cells
were frequently induced from a particular
iPSC line, many siblings might be born in
a region without knowing about their ge-
netic relationships, potentially expanding
an issue that may already be a problem
with sperm donation. The technology
could also be used to produce many em-
bryos, allowing prospective parents to
select their ‘‘best’’ embryo from scores of
options, where their idea of ‘‘best’’ might
be driven by many different ideas of the
‘‘best’’ genetic traits for a child, or even
to create a ‘‘savior sibling’’ primarily to
provide transplantation therapy for a rela-
tive. The clinical uses of induced germ
cells would greatly expand the current is-
sues that ART already confronts. Broad
and open discussions with the general
public as well as medical, scientific, and
ethical experts will be essential.
Furthermore, a different set of contro-
versies might be raised if one could
induce oocytes from XY (chromosomally
male) cells or induce sperm from XX
(chromosomally female) cells (The Hinx-
ton Group, 2008), however remote this
possibility may be. Researchers will have
to justify such research to the public in
terms of both scientific plausibility and
medical benefits.
Conclusion: Reconsidering
Regulations
Research on differentiation of germ cells
from human iPSCs raises many ethical,Cell Stem Cell 1legal, and social implications. Herein, we
reconsider the regulations. A retrospec-
tive look at ART reveals a complicated
history. Some technologies that were
once considered controversial, such as
intrauterine insemination and IVF, are
now considered and accepted as main-
stream, with an estimated 5 million births
aided by IVF to date (Lomax and Troun-
son, 2013). Human induced germ cells
could aid even more people.
However, if we are to fully harness the
potential of human induced germ cells
generated from hiPSCs for medical appli-
cations, research that involves the in vitro
creation of human embryos and subse-
quent culture for a short period is likely to
be necessary. In vitro human embryo cul-
ture until the 14th day is currently viewed
as the ethically permitted maximum
period to assess developmental potential
of the induced germ cells. If this time win-
dow is insufficient to provide scientific
grounding for clinical uses of the induced
germ cells, additional measures might be
necessary to evaluate details of differenti-
ation potential and whether imprinted
genes are expressed exclusively from
either the paternal or the maternal alleles.
The countries, including Japan, that are
currently restrictive to human embryo
research would benefit from increasing
their flexibility when formulating their
cautious regulations regarding embryo
creation using induced germ cells if those
countries would like to fulfill the potential
medical value of the induced germ cells.
Those countries will need to consider
research justifications and decide
whether they should permit such research
or not. In contrast, countries that currently
permit embryo research, including theUS,
would benefit from added clarity and
caution to their more flexible regulations
in light of the moral respect owed to hu-
man embryos. Researchers will have to
act openly and justify the research to the
public based on both scientific rationality
and medical benefit. All countries where
such research is undertaken will need
continuous discussion of the require-
ments for ethical research and proper clin-
ical applications of induced germ cells.
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